 |
Clinical Risk |
 |
Home Site Map This Site Is For Sale |
Clinical Risk
Webinar - Clinical Risk Management BasicsJul 12, 2011 Ambulatory care providers and centers face many professional liability risks, including risks related to obstetrics, diagnosis and treatment, and medication-related patient safety issues. Identifying and implementing effective risk management strategies can be challenging. ECRI Institute's Webinar, "Clinical Risk Management Basics" provides an overview of clinical risk management for ambulatory care, focusing on risk identification, prevention, and control. 
Webinar - Clinical Risk Management - Program IntroductionJan 24, 2011 February 8-12, 2010 This Webinar provides an overview of the Clinical Risk Management Services Web site and demonstrates how to use the e-Learn system to obtain continuing medical education (CME) credits. During this 30-minute Webinar, members from the ECRI Institute staff highlight the resources and use of the Web site and education system. 
Clinical Risk Self-Assessment for GP practices -- What's involved?Mar 16, 2011 Julie Wilson, Clinical Risk Programme Manager, explains what's involved in an MPS Clinical Risk Self-Assessment (CRSA). CRSA's are available to GP practices in the UK and Ireland. For further information, visit: www.mps.org.uk/crsa. 
The Moral Risk of Clinical Drug Trials in Developing CountriesJul 14, 2010 The Moral Risk of Clinical Drug Trials in Developing Countries, Risks to the organisation 
Kidney Transplant: Risks and OutcomesNov 04, 2011 The UCSF Transplant Update Series brings the latest clinical information for physicians, nurses, allied health professionals and others who care for organ failure patients. This program provides an update in transplant outcomes at UCSF by Stephen Tomlanovich, MD, a survey of current clinical trials in kidney transplant by Flavio Vincenti, MD, and vital information on evaluating risks for potential kidney donors by Andrew Posselt, MD Series: UCSF Transplant Update [9/2007] [Health and Medicine] [Professional Medical Education] [Show ID: 12987] 
Biomarkers for Type 2 Diabetes PreventionNov 05, 2011 Simin Liu is currently Professor of Epidemiology and Medicine, founding director of the Program on Genomics and Nutrition at the UCLA School of Public Health and co-founder of the Burroughs Wellcome Fund Interschool Training Program in Metabolic Diseases. Lius current research is at the interface of nutrition and genetics/genomics and focuses on their interplay in affecting major chronic diseases in human populations. He discusses translating epidemiologic observations to clinical risk stratification and intervention in type 2 diabetes. Series: Translational Research for Metabolic Disease Prevention [2/2010] [Health and Medicine] [Professional Medical Education] [Show ID: 17967] 
Dr. Simin Liu, Metabolic Disease PreventionAug 26, 2011 Faculty speaker: Dr. Simin Liu, Biomarkers for type 2 diabetes prevention: translating epidemiologic observations to clinical risk stratification and intervention from the UCLA Symposium, Translational Research for Metabolic Disease Prevention: From Molecules to Populations. Held by the newly formed UCLA Center for Metabolic Disease Prevention, this symposium explores the interdisciplinary study of metabolic diseases and focuses on the need for integration from molecules to populations to curb this epidemic. (www.mdtp.mednet.ucla.edu 
Mayo Clinic Study on Radiation Risks of AngioplastyAug 12, 2011 Body size, gender and the complexity of heart disease significantly influence how much cumulative radiation skin dose that patients receive during percutaneous coronary intervention (PCI) therapy, also known as angioplasty, according to a new Mayo Clinic study. The study was undertaken as a quality control initiative to reduce the potential radiation risks of cancer to patients and PCI operators. Presented today at the annual meeting of the American College of Cardiology, the review of 14 months worth of radiation data from 1827 adult patients is an important early step in understanding ways to improve PCI safety and quality while optimizing therapeutic benefits. The Mayo Clinic study identified 20 clinical traits and circumstances that help predict whether a patient likely received higher or lower doses of radiation. Significance Identifying optimal means of using radiation in PCI is important because a chief advantage of PCI is its minimally-invasive nature in successfully opening vessels and placing stents, which makes it an increasingly popular option for treating select cases of heart disease. PCIs minimally-invasive advantages include reducing patient trauma, speeding recovery and lowering costs, compared to traditional heart surgeries. However, PCI owes its precision, safety and effectiveness to the X-ray fluoroscopy imaging used. X-ray fluoroscopy produces many images to make a movie that allows physicians to visualize the intricate vessel anatomy being treated ... 
Molecular Allergy Component TestingNov 04, 2011 This video is intended for US visitors. Molecular level diagnostic testing represents an exciting advancement in the understanding of the allergen source causing symptoms and the potential severity of the patient's symptoms. The testing allows for differentiation of whether or not allergic symptoms are caused by a primary, species specific allergen component or due to cross-reactivity to a protein found in a variety of allergen sources. This contributes to a more exact diagnosis, enables a more accurate disease prognosis in terms of tolerance development or risk assessment leading to an improved patient management. Molecular Allergy makes it possible to: - assess the clinical risk for reaction - explain symptoms due to cross-reactivity - identify the right patients for specific immunotherapy 
Recognising Risk and Improving Patient Safety - Mildred's StoryNov 21, 2011 Patient Safety - Mildred's Story Mildred's Story was produced to form part of a 'Recognising Risk and Improving Patient Safety' course. The course takes a novel approach to educating healthcare professionals about the importance of non-clinical skills, behaviour and attitudes in assuring patient safety. It draws upon the experiences of patients within healthcare settings, and knowledge gained from other high-risk industries, to develop a strategy enabling healthcare workers to critically appraise and intervene in the development of patient risk. Mildred's Story has been reconstructed from the actual experiences of a number of patients. Part One (Mildred's Flat) Introductory/Exemplary Care Part Two (A & E Department) Situational Awareness Part Three (Care of the Elderly Ward) Communication Part Four (Outside Theatre) Leadership Part Five (Recovery Room) Empowerment Part Six (Orthopaedic Ward) Empowerment The film was produced with financial assistance from the National Patient Safety Agency. It was directed and filmed by University of Leicester ITS-Multimedia Services and written by Paul Allsop, Steve Overton, Nicole Stewart and Paul Stewart. 
CMR OverviewJan 18, 2012 The current definition of the metabolic syndrome encompasses a cluster of metabolic abnormalities linked to insulin resistance, which is often associated with a high-risk form of overweight/obesity: excess abdominal obesity. Because these abnormalities increase the risk of cardiovascular disease (CVD) and type 2 diabetes, numerous consensus groups have attempted to provide guidelines to identify patients in clinical practice with these atherogenic/diabetogenic metabolic abnormalities. Although the number of publications on the metabolic syndrome is soaring, the concept of a cluster of abnormalities including obesity, diabetes, dyslipidemia, and hypertension is not new and several physicians/investigators contributed to the development of this concept through astute clinical observations or epidemiological/metabolic studies. However, a clinical diagnosis of the metabolic syndrome is not sufficient to assess the risk of CVD. In order to properly evaluate and manage global CVD risk in clinical practice, it is important to take into account the risk associated with traditional risk factors as well as the potential additional contribution of abdominal obesity/insulin resistance and related complications. This global risk is referred to as global cardiometabolic risk. 
H1N1 Vaccine Miscarriage RiskNov 28, 2011 It is stated plainly in the Arepanrix adjuvanted H1N1 vaccine package that the product was associated with miscarriage, birth defects and developmental delays in rats.Nonetheless, our government continues to recommend that pregnant women take the adjuvanted vaccine if flu rates are increasing and they are unable to get the unadjuvanted version at that time. How can our public health officials consider this an acceptable risk/benefit ratio?About 1 in 450 pregnant women who catch influenza will go on to develop complications. According to data from Australian epidemiological surveillance, one in 3800 pregnant women are hospitalized for flu-related complications, but these women had other risk factors such as obesity. The risk of pregnant women dying from flu was found to be about 1/300000. articles.mercola.com So far, there has only been one "H1N1-related" death in a pregnant woman in Canada since the virus first appeared in April, and this woman actually died of blood loss following an emergency C-section done because she was suffering respiratory distress. In other words, the flu was only very loosely connected to a single death. Meanwhile, the vaccine has to date never been tested in pregnant women and is known to have adverse outcomes in the offspring of treated rats. Clinical trials on pregnat women were SUSPENDED because the women developed fever, which is known to affect fetal development. Whether the public health officials are totally incompetent or are being ... 
Genetics Counseling for Ovarian Cancer RiskAug 18, 2010 One in 10-12 women with ovarian cancer has a hereditary cause of the ovarian cancer. Carefully collected three-generation pedigrees can help to determine which women should pursue genetic testing for hereditary causes of ovarian cancer, says Dr. Mary S. Beattie in this interview. Mary S. Beattie, MD Associate Clinical Professor of Medicine; Director, Clinical Research, UCSF Cancer Risk Program UCSF Helen Diller Family Comprehensive Cancer Center 
Breast Cancer Incidence Risk Factors Prevention and Treatment for Younger WomenJan 10, 2012 Judy Luce, MD Clinical Professor, Department of Medicine (Hematology/Oncology), UCSF Director of Oncology Services, San Francisco General Hospital explores risk factors, prevention and treatment in younger women. Series: "Breast Cancer Prevention and Treatment" [1/2012] [Health and Medicine] [Show ID: 22921] 
What is a low, intermediate and high risk prostate cancer?Feb 22, 2011 Progress has been made in using the Gleason score, the PSA and the clinical tumor stage to separate prostate cancers into three groups; low risk, intermediate risk and high risk tumors. This video explains the differences and how the information can be used to select the right treatment. 
|
|
||||||||
